Kardigan develops novel therapeutics focused on addressing major cardiovascular diseases like genetic dilated cardiomyopathy and calcific aortic valve stenosis. The company utilizes its "Cardiac Intelligence" platform to modernize the discovery and development of targeted treatments for heart conditions. Their pipeline aims to create medical interventions for conditions that currently carry significant morbidity and mortality risks.
Funding
$300M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PAFounders
Product
Problem
Cardiovascular disease remains the leading cause of death globally, with significant unmet needs in effectively treating diverse patient populations and subtypes of disease. Current treatments often focus on symptom management rather than addressing the underlying disease mechanisms, resulting in suboptimal outcomes for many patients.
Solution
Kardigan is a biopharmaceutical company focused on modernizing cardiovascular drug development through a personalized medicine approach. The company leverages a proprietary cardiac-specific R&D platform, termed "Cardiac Intelligence," to identify critical disease drivers and match them with treatment responders. By integrating cutting-edge discovery, translational research, and strategic in-licensing, Kardigan aims to develop a portfolio of disease-modifying medicines that target the underlying pathophysiology of cardiovascular disease. This approach enables effective patient segmentation and streamlined clinical trials, delivering novel therapies to patients who have the greatest potential to benefit.
Target Audience
Kardigan's primary target audience includes patients with cardiovascular diseases, particularly those with primary and secondary cardiomyopathies leading to heart failure, as well as clinical researchers and healthcare providers focused on cardiovascular medicine.
Features
- Proprietary Cardiac Intelligence R&D platform for deep understanding of drug mechanisms and patient responses
- Portfolio of late-stage clinical candidates designed to target critical disease drivers
- AI technology-enhanced clinical trials leveraging Prolaio's health technology expertise
- Tech-enabled clinical trial enrichment capability to translate high-density data into insights
- FDA-cleared software to increase statistical power, improve patient screening and compliance
- Identification of patient subgroups and tracking of safety and efficacy signals with greater accuracy
- Integration of AI-based tools and continuous real-world measurements to optimize clinical study design